Process Excellence in the Pharmaceutical Industry

In the past, value creation was mainly based on intellectual property, market exclusivity and the blockbuster business model was the major source of cash.

Today, the reality is characterised by:

  • Shrinking research

  • Development productivity, and

  • Cost reduction initiatives

This is mostly driven by governmental pressure, shifting global growth, increased regulatory requirements and loss of market exclusivity for many of the blockbuster drugs. Despite the steadily increasing pressure, the industry remains optimistic. However, it still needs to find new solutions to fundamental strategic issues.

Based on pharmaceutical and biotechnology data from PEX Network's biennial State of
the Industry Survey. The following infographic created by Pharma IQ is a summary results
that will enable you to get a better understanding emerging trends in process excellence in the pharmaceutical and biotechnology industries. Discover which process excellence methodologies are being employed by pharmaceutical companies, annual budgets for process excellence within the pharmaceutical industry, the number of full time resources devoted to process excellence and how success is measured.